Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Hong Kong · Delayed Price · Currency is HKD

9.26

+0.17 (1.82%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	4.79B
Revenue (ttm)	119.28M +223.3%
Net Income	-242.37M
EPS	-0.49
Shares Out	517.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,453,081
Open	9.20
Previous Close	9.09
Day's Range	9.01 - 9.77
52-Week Range	8.01 - 96.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenal ulcer, adult reflux esophagitis, pylori eradication; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer, R+/HER2- locally advanced or metastatic breast cancer, and adjuvant therapy for HR+/HER2- early breast cancer; and XZP-3621, a first-line treatmen... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2008

Employees 342

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2575

Full Company Profile

Financial Performance

In 2025, Xuanzhu Biopharmaceutical's revenue was 51.77 million, an increase of 72.03% compared to the previous year's 30.09 million. Losses were -245.51 million, -55.88% less than in 2024.

Financial numbers in CNY Financial Statements